论文部分内容阅读
[目的]评价伊立替康(CPT-11)联合顺铂(DDP)治疗晚期食管癌的疗效及不良反应。[方法]17例患者均经病理学或细胞学确诊为晚期食管癌,全部病例均有客观评价指标。采用CPT-1160mg/m2,静脉滴注,d1、8;DDP30mg/m2,静脉滴注,d1、8;28d为一周期,连续用2周期后评价疗效及不良反应。[结果]17例均完2个周期化疗,共接受38个周期化疗,全部病例均可评价疗效及不良反应。无完全缓解(CR)病例,部分缓解(PR)7例(41.2%),稳定(NC)2例(11.8%),进展(PD)8例(47.1%),有效率为41.2%;中位生存时间为(MST)9.1个月。不良反应主要是骨髓抑制,恶心、呕吐,腹泻,III-IV级粒细胞减少,血小板减少,恶心、呕吐,腹泻的发生率分别为17.6%,11.8%,23.5%,11.8%。[结论]CPT-11联合DDP治疗晚期食管癌有确切疗效,不良反应轻,耐受性好,可作为复发或治疗失败的晚期食管癌治疗的备选方案之一。
[Objective] To evaluate the efficacy and adverse reactions of irinotecan (CPT-11) and cisplatin (DDP) in the treatment of advanced esophageal cancer. [Methods] All 17 patients were diagnosed as advanced esophageal cancer by pathology or cytology, and all the patients had objective evaluation indexes. Using CPT-1160mg / m2, intravenous drip, d1,8; DDP30mg / m2, intravenous drip, d1,8; 28d for a period of two consecutive cycles after the evaluation of efficacy and adverse reactions. [Results] All of the 17 patients were treated with 2 cycles of chemotherapy and received 38 cycles of chemotherapy. All cases were evaluated for efficacy and adverse reactions. There were 7 cases (41.2%) of partial remission (PR), 2 cases (11.8%) of stable (NC) and 8 cases (47.1%) of progression (PD) without complete remission Survival time (MST) 9.1 months. Adverse reactions were mainly bone marrow suppression, nausea, vomiting, diarrhea, grade III-IV neutropenia, thrombocytopenia, nausea, vomiting and diarrhea rates were 17.6%, 11.8%, 23.5% and 11.8%, respectively. [Conclusion] CPT-11 combined with DDP has the exact curative effect on advanced esophageal cancer, with mild adverse reactions and good tolerability. It can be used as an alternative treatment of advanced esophageal cancer with recurrent or failed treatment.